We are live on
!
Find out more
AC
Amia Capital Portfolio holdings
AUM
$32.1M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
-23.58%
1 Year Est. Return
+0.56%
3 Year Est. Return
+30.11%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$112M
AUM Growth
-$230M
(-67%)
Cap. Flow
-$154M
Cap. Flow
% of AUM
-136.76%
Top 10 Holdings %
Top 10 Hldgs %
85.57%
Holding
48
New
7
Increased
2
Reduced
31
Closed
8
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ITCI
Intra-Cellular Therapies Inc.
ITCI
|
+$655K |
| 2 |
Arvinas
ARVN
|
+$506K |
| 3 |
Scholar Rock
SRRK
|
+$309K |
| 4 |
MTEM
Molecular Templates, Inc.
MTEM
|
+$275K |
| 5 |
CDTX
Cidara Therapeutics
CDTX
|
+$69.1K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
|
+$67.2M |
| 2 |
LSXMA
Liberty Media Corporation Series A Liberty SiriusXM Common Stock
LSXMA
|
+$38.1M |
| 3 |
LSXMK
Liberty Media Corporation Series C Liberty SiriusXM Common Stock
LSXMK
|
+$24.8M |
| 4 |
Petrobras
PBR
|
+$9.43M |
| 5 |
GRFS
Grifois
GRFS
|
+$7.93M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 54% |
| 2 | Communication Services | 4.34% |
| 3 | Materials | 3.32% |
| 4 | Energy | 0.05% |
| 5 | Consumer Discretionary | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
SAGE
26
DELISTED
Sage Therapeutics
SAGE
| $320K | 0.28% |
11,159
-2,882
| -21% | -$167K |
|
|
MYOV
27
DELISTED
Myovant Sciences Ltd.
MYOV
| $317K | 0.28% |
41,970
-11,538
| -22% | -$129K |
|
|
AKCA
28
DELISTED
Akcea Therapeutics Inc
AKCA
| $305K | 0.27% |
21,337
-6,880
| -24% | -$113K |
|
|
29
Scholar Rock
SRRK
$5.71B
| $278K | 0.25% |
+22,962
| New | +$309K |
|
30
CRISPR Therapeutics
CRSP
$4.58B
| $270K | 0.24% |
6,365
-2,062
| -24% | -$106K |
|
31
PUT
State Street Technology Select Sector SPDR ETF
XLK
$115B
| $263K | 0.23% |
+525,000
| New | +$24M |
|
|
MTEM
32
DELISTED
Molecular Templates, Inc.
MTEM
| $250K | 0.22% |
+1,256
| New | +$275K |
|
33
MacroGenics
MGNX
$235M
| $229K | 0.2% |
39,389
-5,259
| -12% | -$47.8K |
|
34
Q32 Bio
QTTB
$450M
| $218K | 0.19% |
781
-363
| -32% | -$111K |
|
|
SGMO
35
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
| $214K | 0.19% |
33,555
-3,557
| -10% | -$26.4K |
|
36
Voyager Therapeutics
VYGR
$187M
| $214K | 0.19% |
23,360
+3,677
| +19% | +$42.2K |
|
37
Wave Life Sciences
WVE
$1.12B
| $196K | 0.17% |
20,943
+297
| +1% | +$2.53K |
|
|
KZR
38
DELISTED
Kezar Life Sciences
KZR
| $59K | 0.05% |
+1,352
| New | +$55K |
|
|
CDTX
39
DELISTED
Cidara Therapeutics
CDTX
| $57K | 0.05% |
+1,153
| New | +$69.1K |
|
|
40
Petrobras
PBR
$121B
| $55K | 0.05% |
10,000
-790,000
| -99% | -$9.43M |
|
41
Bristol-Myers Squibb
BMY
$127B
| – | – |
-4,321
| Closed | -$277K |
|
42
iShares MSCI Chile ETF
ECH
$1.01B
| – | – |
-90,000
| Closed | -$3M |
|
|
43
iShares JPMorgan USD Emerging Markets Bond ETF
EMB
$14.9B
| – | – |
-586,300
| Closed | -$67.2M |
|
44
Gilead Sciences
GILD
$161B
| – | – |
-4,746
| Closed | -$308K |
|
45
Lennar Class B
LEN.B
$20B
| – | – |
-33,945
| Closed | -$1.44M |
|
46
Qiagen
QGEN
$8.53B
| – | – |
-64,937
| Closed | -$2.34M |
|
47
UBS Group
UBS
$170B
| – | – |
-25,840
| Closed | -$325K |
|
|
BOLD
48
DELISTED
Audentes Therapeutics, Inc
BOLD
| – | – |
-15,205
| Closed | -$910K |
|
Similar funds
QI
SAM
FCMI
AG
NLG
BEVI
BGDR
TAAM
Amia Capital's Q1 2020 Portfolio in Review
As of Q1 2020, Amia Capital held 48 positions worth $112M, down 67% from $343M the previous quarter. Its ten largest holdings account for 86% of the portfolio.
Amia Capital withdrew a net $154M in Q1 2020, closing 8 positions and reducing 31 holdings. Its most notable exit was iShares JPMorgan USD Emerging Markets Bond ETF, an estimated $67.2M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 54% of assets, up from 26% a quarter earlier, followed by Communication Services and Materials.
Against the trend, Amia Capital opened a new position in Intra-Cellular Therapies Inc. worth $463K.
- Amia Capital's largest Q1 2020 buy was Intra-Cellular Therapies Inc.: 30,144 shares worth $463K.
- Amia Capital added most to Voyager Therapeutics in Q1 2020, an estimated $42.2K increase.
- Amia Capital's biggest Q1 2020 reduction was Liberty Media Corporation Series A Liberty SiriusXM Common Stock, cutting an estimated $38.1M.
- Amia Capital fully exited iShares JPMorgan USD Emerging Markets Bond ETF in Q1 2020, selling an estimated $67.2M.
- Amia Capital's ten largest holdings make up 86% of its $112M portfolio in Q1 2020.
- Amia Capital opened 7 new positions and closed 8 in Q1 2020.
- Amia Capital's portfolio value fell 67% quarter-over-quarter to $112M.
Based on Amia Capital's 13F filing for Q1 2020, filed 15 May 2020.